Literature DB >> 20599013

Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy.

Iacopo Olivotto1, Barry J Maron, Evan Appelbaum, Caitlin J Harrigan, Carol Salton, C Michael Gibson, James E Udelson, Christopher O'Donnell, John R Lesser, Warren J Manning, Martin S Maron.   

Abstract

In hypertrophic cardiomyopathy (HCM), the clinical significance attributable to the broad range of left ventricular (LV) systolic function, assessed as the ejection fraction (EF), is incompletely resolved. We evaluated the EF using cardiovascular magnetic resonance (CMR) imaging in a large cohort of patients with HCM with respect to the clinical status and evidence of left ventricular remodeling with late gadolinium enhancement (LGE). CMR imaging was performed in 310 consecutive patients, aged 42 +/- 17 years. The EF in patients with HCM was 71 +/- 10% (range 28% to 89%), exceeding that of 606 healthy controls without cardiovascular disease (66 +/- 5%, p <0.001). LGE reflecting LV remodeling showed an independent, inverse relation to the EF (B-0.69, 95% confidence interval -0.86 to -0.52; p <0.001) and was greatest in patients with an EF <50%, in whom it constituted a median value of 29% of the LV volume (interquartile range 16% to 40%). However, the substantial subgroup with low-normal EF values of 50% to 65% (n = 45; 15% of the whole cohort), who were mostly asymptomatic or mildly symptomatic (37 or 82% with New York Heart Association functional class I to II), showed substantial LGE (median 5% of LV volume, interquartile range 2% to 10%). This overlapped with the subgroup with systolic dysfunction and significantly exceeded that of patients with an EF of 66% to 75% and >75% (median 2% of the LV volume, interquartile range 1.5% to 4%; p <0.01). In conclusion, in a large cohort of patients with HCM, a subset of patients with low-normal EF values (50% to 65%) was identified by contrast-enhanced CMR imaging as having substantial degrees of LGE, suggesting a transition phase, potentially heralding advanced LV remodeling and systolic dysfunction, with implications for clinical surveillance and management. Copyright (c) 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20599013     DOI: 10.1016/j.amjcard.2010.03.020

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  34 in total

1.  Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function.

Authors:  Ruth F Sommese; Jongmin Sung; Suman Nag; Shirley Sutton; John C Deacon; Elizabeth Choe; Leslie A Leinwand; Kathleen Ruppel; James A Spudich
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

2.  Myocardial fibrosis and quality of life in patients with non-ischemic cardiomyopathy: a cardiovascular magnetic resonance imaging study.

Authors:  Razi Khan; David Massel; John Stirrat; David Scholl; Gerald Wisenberg; Terry Thompson; Maria Drangova; James A White
Journal:  Int J Cardiovasc Imaging       Date:  2012-08-09       Impact factor: 2.357

3.  Extent of late gadolinium enhancement at right ventricular insertion points in patients with hypertrophic cardiomyopathy: relation with diastolic dysfunction.

Authors:  Yinsu Zhu; Eun-Ah Park; Whal Lee; Hyung-Kwan Kim; Ajung Chu; Jin Wook Chung; Jae Hyung Park
Journal:  Eur Radiol       Date:  2015-01-18       Impact factor: 5.315

Review 4.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

5.  Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction.

Authors:  Akira Funada; Hideaki Kanzaki; Teruo Noguchi; Yoshiaki Morita; Yasuo Sugano; Takahiro Ohara; Takuya Hasegawa; Hiromi Hashimura; Hatsue Ishibashi-Ueda; Masafumi Kitakaze; Satoshi Yasuda; Hisao Ogawa; Toshihisa Anzai
Journal:  Heart Vessels       Date:  2015-03-28       Impact factor: 2.037

Review 6.  Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy.

Authors:  Julian O M Ormerod; Michael P Frenneaux; Mark V Sherrid
Journal:  Nat Rev Cardiol       Date:  2016-07-14       Impact factor: 32.419

Review 7.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

Review 8.  Risk Stratification in Hypertrophic Cardiomyopathy.

Authors:  Alexandros Klavdios Steriotis; Sanjay Sharma
Journal:  Eur Cardiol       Date:  2015-07

9.  Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients.

Authors:  Da-Jun Hu; Jing Xu; Wei Du; Jian-Xin Zhang; Min Zhong; Ya-Nan Zhou
Journal:  Int J Cardiovasc Imaging       Date:  2016-08-26       Impact factor: 2.357

10.  Relation of late gadolinium enhancement in cardiac magnetic resonance on the diastolic volume recovery of left ventricle with hypertrophic cardiomyopathy.

Authors:  Xiaorong Chen; Hongjie Hu; Yue Qian; Jiner Shu
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.